Hemodynamic Monitoring, Positive Inotropic and Vasoactive Drugs During Cardiac Surgery (EMOA)
EMOA
1 other identifier
observational
3,099
1 country
1
Brief Summary
Describe the proportion of patients who underwent cardiac surgery in France and benefiting from a monitoring cardiac output, describe the use of positive inotropic and vasoactive agents for cardiac surgery patients operated (type of catecholamines, their duration), describe the fluid replacement and transfusions of first 24 hours, describe the incidence of postoperative complications in patients undergoing cardiac surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2015
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 6, 2015
CompletedFirst Posted
Study publicly available on registry
October 8, 2015
CompletedStudy Start
First participant enrolled
November 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2016
CompletedNovember 30, 2017
November 1, 2017
1 month
October 6, 2015
November 28, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of patients undergoing cardiac surgery and receiving a cardiac output monitoring.
Up to 28 days after surgery (length of intensive care unit stay)
Secondary Outcomes (9)
Correlation between use of cardiac output monitoring and the incidence of norepinephrine use
Up to 28 days after surgery (length of intensive care unit stay)
Correlation between use of cardiac output monitoring and the incidence of dobutamine use
Up to 28 days after surgery (length of intensive care unit stay)
Correlation between use of cardiac output monitoring and the incidence of epinephrine use
Up to 28 days after surgery (length of intensive care unit stay)
Correlation between use of cardiac output monitoring and the length of norepinephrine infusion
Up to 28 days after surgery (length of intensive care unit stay)
Correlation between use of cardiac output monitoring and the length of dobutamine infusion
Up to 28 days after surgery (length of intensive care unit stay)
- +4 more secondary outcomes
Eligibility Criteria
Patients receiving elective cardiac surgery during the study period
You may qualify if:
- Patients over 18 years old undergoing cardiac surgery during the study period
- age under 18 years old
- Extracorporeal life support and others cardiac assistance
- congenital cardiac surgery
- TAVI procedures
- Pericardium surgical drainages
- Sternal sepsis surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Caen University Hospital
Caen, France
Study Officials
- PRINCIPAL INVESTIGATOR
Marc-Olivier Fischer
University Hospital, Caen
- PRINCIPAL INVESTIGATOR
Fabien Dechanet
University Hospital, Caen
- PRINCIPAL INVESTIGATOR
Raphaël D'Orlando
University Hospital, Caen
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 6, 2015
First Posted
October 8, 2015
Study Start
November 1, 2015
Primary Completion
December 1, 2015
Study Completion
January 1, 2016
Last Updated
November 30, 2017
Record last verified: 2017-11